Oliver Engert Buys 1,000 Shares of Enovis (NYSE:ENOV) Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert bought 1,000 shares of Enovis stock in a transaction dated Monday, June 15th. The shares were acquired at an average cost of $20.92 per share, with a total value of $20,920.00. Following the completion of the purchase, the insider owned 53,640 shares in the company, valued at approximately $1,122,148.80. This trade represents a 1.90% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Oliver Engert also recently made the following trade(s):

• On Thursday, June 11th, Oliver Engert bought 1,200 shares of Enovis stock. The shares were acquired at an average cost of $21.62 per share, with a total value of $25,944.00.
• On Wednesday, June 10th, Oliver Engert bought 1,000 shares of Enovis stock. The shares were acquired at an average cost of $23.00 per share, with a total value of $23,000.00.
• On Monday, June 1st, Oliver Engert bought 1,000 shares of Enovis stock. The shares were acquired at an average cost of $22.22 per share, with a total value of $22,220.00.

Enovis Stock Down 3.5%

Shares of ENOV opened at $20.83 on Thursday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. Enovis Corporation has a one year low of $20.55 and a one year high of $36.82. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of -1.05 and a beta of 1.38. The stock has a 50 day moving average price of $23.94 and a 200 day moving average price of $24.37.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, topping the consensus estimate of $0.82 by $0.07. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The firm had revenue of $589.15 million during the quarter, compared to analysts’ expectations of $572.02 million. During the same period in the previous year, the business earned $0.81 earnings per share. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities research analysts forecast that Enovis Corporation will post 3.65 earnings per share for the current fiscal year.

Institutional Trading of Enovis

A number of hedge funds and other institutional investors have recently modified their holdings of ENOV. AQR Capital Management LLC increased its stake in shares of Enovis by 12.5% in the 1st quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock worth $2,363,000 after acquiring an additional 7,072 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Enovis by 37.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock worth $10,226,000 after acquiring an additional 73,116 shares during the last quarter. Empowered Funds LLC increased its stake in shares of Enovis by 13.0% in the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after acquiring an additional 749 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after acquiring an additional 707 shares during the last quarter. Finally, Amundi increased its stake in shares of Enovis by 24,405.0% in the 2nd quarter. Amundi now owns 9,802 shares of the company’s stock worth $328,000 after acquiring an additional 9,762 shares during the last quarter. 98.45% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently commented on ENOV shares. Needham & Company LLC boosted their price target on Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. William Blair started coverage on Enovis in a research report on Friday, April 17th. They set an “outperform” rating for the company. Zacks Research cut Enovis from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 1st. Wells Fargo & Company dropped their price target on Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Finally, Evercore reiterated an “outperform” rating and set a $36.00 price target on shares of Enovis in a research report on Friday, May 8th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Enovis currently has an average rating of “Moderate Buy” and an average target price of $44.50.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.